Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.02.2014 | short review

Surgical controversies in esophageal cancer

verfasst von: Sebastian F. Schoppmann, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Several controversies concerning the optimal surgical management of esophageal cancer exist. The extent of resection, the surgical approach, the optimal lymph node dissection, and the volume–outcome relationship potentially influence the overall outcome of patients undergoing a surgical treatment for esophageal cancer. Especially in the context of perioperative, randomized studies in esophageal cancer, it appears indispensable to understand the broad range of quality indicators of esophageal cancer surgery.
Vorheriger Artikel Untreated endometrial cancer: a case report and a review of the literature
Nächster Artikel Wild-type GIST: a comprehensive review
Literatur
1.
Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005 Jan 19;97(2):142–6. PubMed PMID: 15657344.
2.
Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013 Feb 2;381(9864):400–12. PubMed PMID: 23374478.
3.
Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007 Mar;8(3):226–34. PubMed PMID: 17329193.
4.
Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002 Nov 21;347(21):1662–9. PubMed PMID: 12444180.
5.
Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007 Dec;246(6):992–1000. Discussion 1001. PubMed PMID: 18043101.
6.
Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998 Nov;85(11):1457–9. PubMed PMID: 9823902.
7.
Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006 Aug;7(8):644–51. PubMed PMID: 16887481.
8.
Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008 Oct;248(4):549–56. PubMed PMID: 18936567.
9.
Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Holscher A, Law S, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg. 2008 Dec;248(6):979–85. PubMed PMID: 19092342.
10.
Wouters MW, Gooiker GA, van Sandick JW, Tollenaar RA. The volume-outcome relation in the surgical treatment of esophageal cancer: a systematic review and meta-analysis. Cancer. 2012 Apr 1;118(7):1754–63. PubMed PMID: 22009562.
11.
Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002 Aug;236(2):177–83. PubMed PMID: 12170022. Pubmed Central PMCID: 1422563.
12.
Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg. 2004 Dec;240(6):962–72. Discussion 972–4. PubMed PMID: 15570202. Pubmed Central PMCID: 1356512.
13.
Decker G, Coosemans W, De Leyn P, Decaluwe H, Nafteux P, Van Raemdonck D, et al. Minimally invasive esophagectomy for cancer. Eur J Cardiothorac Surg. 2009 Jan;35(1):13–20. Discussion 21. PubMed PMID: 18952454.
14.
Derogar M, Sadr-Azodi O, Johar A, Lagergren P, Lagergren J. Hospital and surgeon volume in relation to survival after esophageal cancer surgery in a population-based study. J Clin Oncol. 2013 Feb 10;31(5):551–7. PubMed PMID: 23295792.
15.
Dikken JL, Henneman D, Putter H, Lemmesn VEPP, Van der Geest LG, Van Hillgersberg R, et al.  Centralization of esophagectomy for cancer: how far should we go? Eur J Cancer. 2013. Abstract ESMO. Amsterdam, The Netherlands, 1. October 2013.
Metadaten
Titel
Surgical controversies in esophageal cancer
verfasst von
Sebastian F. Schoppmann, MD
Publikationsdatum
01.02.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0129-9

Weitere Artikel der Ausgabe 1/2014

Cure and care for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries: part II

  • editorial

Multi-gene signatures in breast cancer: actual clinical impact

  • short review

The importance of HPV vaccination today

  • editorial

Untreated endometrial cancer: a case report and a review of the literature

  • short review

Treatment and clinical results in childhood AML in Greece

  • short review

Evaluation of EGFR, KRAS, and TP53 mutations as predictive of disease recurrence in resected early non-small cell lung carcinomas (NSCLCs)

  • original report